Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
PMID: 34003802
When to Speak to Your GP About Hunger on Wegovy Whilst some hunger during Wegovy treatment can be normal, particularly in early treatment phases, certain situations warrant medical review to ensure treatment optimisation and exclude underlying issues
Many patients experience a small initial weight increase (often water or glycogen, not fat) that stabilizes quickly
Its weakest point is billing: the most common complaint is being charged before full approval or having trouble canceling
In this vulnerable population, only 8.47% participants receiving liraglutide reported gastrointestinal side effects (38)